Trial Profile
A Double Blind, Randomised, Placebo Controlled, Parallel Group Study of Sativex, in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Jan 2022
Price :
$35
*
At a glance
- Drugs Nabiximols (Primary)
- Indications Muscle spasticity
- Focus Registrational; Therapeutic Use
- Sponsors GW Pharmaceuticals
- 21 May 2012 New trial record